A Phase III Study of Nivolumab in Combination with Chemo-Immunotherapy to Treat Newly Diagnosed Primary Mediastinal B-Cell Lymphoma


Full Title

A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma (ANHL1931) (CIRB)


Treatment for primary mediastinal B-cell lymphoma (PMBCL) includes chemotherapy plus an immunotherapy drug called rituximab. Rituximab binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells.

Nivolumab is a type of immunotherapy drug that boosts the immune system to find and kill cancer cells. In this study, researchers want to see if giving nivolumab with chemo-immunotherapy is better than chemo-immunotherapy alone. The people in this study have PMBCL that has not yet been treated.

If you join this study, you will be randomly assigned to get chemo-immunotherapy with or without nivolumab. Nivolumab and chemo-immunotherapy are given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You or your child must:

  • Have newly diagnosed PMBCL.
  • Have normal heart and kidney function.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 2 or older.


For more information about this study and to see if you or your child can join, please contact 1-833-MSK-KIDS.




Phase III (phase 3)

Disease Status

Newly Diagnosed

ClinicalTrials.gov ID